Lattice Medical secures €43 million to push resorbable 3D printed implants from trials to production

French medtech Lattice Medical announced a €43 million Series B round on 23 October 2025. The company says the funds will accelerate clinical development of its lead product MATTISSE and a second device called RODIN. The financing is among the largest medtech deals in France in 2025 and is presented as a vehicle to build local industrial capacity in Lille and expand into contract manufacturing. The operation brings together public strategic capital under France 2030 and private investors including an EU-backed deep tech investor.

The deal and who is backing it

Lattice Medical’s Series B is led by the SPI Fund, which is managed by Bpifrance on behalf of the French government as part of the France 2030 investment plan. Other participants include Blast.Club, Singapore based Sprim, qualified investors mobilised via TIDJEE, and returning investors EIC Fund, Captech Santé, Nord France Amorçage and FIRA Nord Est. The package also includes non-dilutive loans from banking partners and earmarked grants or support from two France 2030 programmes named M3DINPRINT and LIPOTEC. Legal and transaction advisors named in company materials include AVOLTA, McDermott Will Emery and TIDJEE.

What the company makes and how it works

The basic clinical idea is to offer an autologous, resorbable scaffold that supports tissue regeneration and then gradually degrades. That contrasts with permanent synthetic implants and aims to reduce long term foreign body presence. The scientific and commercial challenge for such devices is to show durable functional and aesthetic outcomes over multi year follow up while meeting sterility and reproducibility requirements in production.

How Lattice plans to use the €43 million

The company positions the new facility as both a production site for its own implants and as a way to support a regional medtech supply chain. The financing mix includes equity, non-dilutive bank financing and targeted public programmes under France 2030. That combination is typical for capital intensive medtech projects that require both R&D and regulated scale manufacturing.

Context, market and strategic claims

Lattice cites World Health Organization figures that about 2 million new breast cancer cases occur yearly and that only around 30 percent of women who undergo mastectomy opt for reconstruction. The company argues its resorbable, autologous-focused approach meets a growing demand for more natural and less invasive reconstruction options. Company statements position the fundraising as a turning point to become a leader in soft tissue reconstruction and to contribute to regional reindustrialisation in France.

Why the promise is plausible

Resorbable scaffolds and personalised 3D printed implants are an active research area and could address clinical demand for alternatives to permanent silicone or saline implants. Controlling manufacturing locally reduces logistical complexity and can accelerate iterative development. Backing by public industrial funds under France 2030 and the EIC Fund signals institutional confidence in the technology and the company's industrial strategy.

Key risks and uncertainties

Despite the positive framing, multiple hurdles remain. The products are still in clinical trials and will need robust, long term outcome data to secure regulatory approvals and clinical adoption. Scaling 3D printing in clean rooms with resorbable biomaterials requires validated quality systems, supply chain resilience and reproducible device performance. Market access will depend on reimbursement decisions, surgeon training and competitive responses from established implant manufacturers.

Funding ecosystem and industrial policy angle

The deal is a good example of how public strategic funds and private investors are combining to back deep tech medtech companies in Europe. France 2030 aims to drive industrial renewal by channeling capital into projects with manufacturing potential. The SPI Fund is explicitly targeted at industrialisation. The presence of the EIC Fund links Lattice back to EU deep tech support mechanisms that combine grants, blended finance and equity to bridge the so called valley of death between research and commercialisation.

That public backing reduces some funding risk but does not remove execution risk. Industrialisation and market entry remain the most expensive and time consuming phases for device companies, especially those working with novel biomaterials and personalised manufacturing.

Investors, advisors and partners named by the company

Implications and outlook

Lattice Medical’s financing milestone is notable for the French medtech scene. The combination of public strategic capital and private investors gives the company a runway to advance trials and to invest in manufacturing. That could help the company extend its platform to other soft tissue indications if clinical results are supportive.

At the same time the market narrative that a single round will 'reinvent' reconstruction is premature. The coming 18 to 36 months will be decisive around trial readouts, regulatory submissions, scale up of clean room production and early commercial contracts. Investors and stakeholders should watch for independent clinical data, regulatory milestones and evidence of reproducible manufacturing before concluding that the technology has achieved broad clinical or commercial success.

Further reading and sources

This article is based on the company press release published 23 October 2025 and publicly available materials from Lattice Medical, Bpifrance and the EIC Fund. Additional context on France 2030 and the SPI Fund comes from French government programme materials.